Pharmacokinetics of conivaptan hydrochloride, a vasopressin V1A/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study
Authors:
- Dennis StalkerDSDennis Stalker
- James KeirnsJKJames Keirns
- 1 July 2009
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 31 (7) , 1542-1550